How can we use AI to program antibodies?
Episode 29 of the The Pharma Letter Podcast podcast, hosted by Simon Wentworth, titled "How can we use AI to program antibodies?" was published on November 14, 2024 and runs 16 minutes.
November 14, 2024 ·16m · The Pharma Letter Podcast
Summary
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Design, a company that is working on programmable antibodies. Biolojic's platform has already yielded a first-of-its-kind computationally designed antibody, now in Phase II trials, as well as a pipeline aimed at autoimmune and inflammatory conditions. The firm ...
Episode Description
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases.
We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Design, a company that is working on programmable antibodies.
Biolojic's platform has already yielded a first-of-its-kind computationally designed antibody, now in Phase II trials, as well as a pipeline aimed at autoimmune and inflammatory conditions.
The firm has also forged collaborations with major players in the industry, including fellow Israeli firm Teva (NYSE: TEVA), as well as Eli Lilly (NYSE: LLY) and Germany’s Merck KGaA (MRK: DE).